Week in Review: China Pharma Financing Deals
January 31, 2016 at 05:11 AM EST
CARsgen Therapeutics, a Shanghai company developing CAR-T immunotherapies for solid tumors, completed a $30m Series B round. CARsgen is currently conducting Phase I trials of two CAR-T immunotherapies: for brain, and liver cancers.
